CSL LimitedASX: CSL

CSL enters exclusive agreement with Alentis Therapeutics

· Issued by CSL Limited

Filed with ASX · · 2 pages · English

Summary by 6ix AI

CSL Limited has entered into an exclusive agreement with Alentis Therapeutics to co-develop and promote lixudebart, a treatment for rare kidney and liver diseases. CSL will make an initial payment and fund further trials, with profits shared between the two companies upon commercialization. This agreement reflects CSL's strategy to enhance its nephrology portfolio through external partnerships.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/csl-enters-exclusive-agreement-with-alentis-therapeutics

Watch CSL's latest callCSL (ASX:CSL) Q4 2026 Earnings Call · Replay · Aug 18Read the transcript of CSL (ASX:CSL) Q4 2026 Earnings Call

Release

ASX Announcement Page | 1 5 October, 2026 Melbourne, Australia CSL enters exclusive agreement for rare kidney and liver disease treatment CSL Limited (ASX:CSL; USOTC:CSLLY) today announces it has entered into an agreement with Alentis Therapeutics to co-develop and co-promote lixudebart, a...

CSL Limited on 6ix

Earlier from CSL

Later from CSL

All CSL news releases